MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds
Previous
Next

thought leadership

Report: Reinventing product and portfolio value for the biopharmaceutical industry

9/14/2023

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of stakeholders earlier than you think.

The last decade has seen a notable rise in complex medicines, which target smaller and more specific patient populations and have novel modes of action. Often, determining the value of these treatments requires knowledge and communications about novel biomarkers, newer forms of evidence, and complex clinical pathways.

An interconnected network of stakeholders— regulators, payers, healthcare professionals, patients, and carers—therefore need to comprehend vast amounts of information to determine a product’s value above the standard of care. Each of these stakeholders have overlapping and distinct information needs, and it is unlikely their requirements can be fully addressed by clinical trials alone.

The regulatory environment is supportive of accelerated approvals based on Phase 2 single-arm studies and surrogate endpoints, leading to significant uncertainty for payers looking to understand the incremental treatment benefit of a product versus a reimbursed standard of care. This tension has created challenges for manufacturers who must fully understand different stakeholders’ needs and develop integrated plans to deliver against these requirements.

Biopharmaceutical companies need to rethink their approach to clinical and economic value. Taking a structured approach will help uncover stakeholders’ questions and knowledge gaps at the earliest phases of clinical development.

By collaborating cross-functionally, manufacturers can build a holistic picture of each stakeholder upfront and create early alignment around the evidence gaps and benefits that will resonate with their target stakeholders. These insights will determine the evidence-generation plan, in turn improving clinical study design, generating focused patient insights, and providing the foundation for the real-world evidence strategy. Most importantly, patients’ lives and their health outcomes can be improved.

In this report, our MedicalConsultingPolicy, Access, Value, and Evidence experts detail the practicalities of taking this multistakeholder approach, which emphasizes the benefits that resonate with each stakeholder group.

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Avalere Health website, such as the pages you visit.

For more information, check the cookie statement

32E8261E-A569-4B66-ACC6-3CB772DDEDEE

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on avalerehealth.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Avalerehealth.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.